BioMarin drug for genetic disorder succeeds in late-stage study
March 21, 2016 at 06:22 AM EDT
March 21 (Reuters) - BioMarin Pharmaceutical Inc said preliminary data showed its experimental drug met the main goal of reducing blood phenylalanine in patients with a genetic disorder, in a late-stage study.